Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
OwnerPramod Srivastavainventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to complexes and fusion proteins comprising a CD91 ligand and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides complexes comprising a CD91 ligand non-covalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising a CD91 ligand fused via a peptide bond to an antigenic molecule.
Claims10
A purified, immunogenic complex comprising an antigenic molecule noncovalently bound to a CD91 ligand, and wherein the CD91 ligand is selected from the group consisting of
- ApoE, Lipoprotein lipase, Hepatic lipase, Factor IXa, Factor VIIIa, Factor VIIa/TFPL MWP-13, MMP-9, Spingolipid activator protein, PAI-1, Antithrombin III, Tissue factor pathway inhibitor (TFPI), Heparin cofactor II, APP, Thrombospondin-1, Thrombospondin-2, Pseudoinonas exotoxin A, Lactoferin, Rhinovirus and RAP.
A method for preparing immunogenic, in vitro complexes of a CD91 ligand associated with one or more antigenic molecules, said method comprising:
- a) incubating a CD91 ligand and one or more antigenic molecules under conditions and for a length of time sufficient for formation of immunogenic complexes of the CD91 ligand noncovalently bound to the antigenic molecules;
- and
- b) isolating said complexes;
- wherein the CD91 ligand is selected from the group consisting of ApoE, Lipoprotein lipase, Hepatic lipase, Factor IXa, Factor VIIIa, Factor VIIa/TFPI, MMP-13, MM-9, Spingolipid activator protein, PAI-1, Antithrombin III, Tissue factor pathway inhibitor (TFPI), Heparin cofactor II, APP, Thrombospondin-1, Thrombospondin-2, Pseudomnonas exotoxin A, Lactoferrin, Rhinovirus and RAP.
A method of treating or preventing cancer or an infectious disease in a subject comprising administering to the subject an amount of a purified complex comprising an antigenic molecule noncovalently bound to a CD91 ligand effective to treat or prevent cancer or an infectious disease, wherein the antigenic molecule displays the antigenicity of a cancer-associated or cancer-specific antigen, or of an antigen of an infectious agent that causes the infectious disease, respectively, and the CD91 ligand is selected from the group consisting of
- ApoE, Lipoprotein lipase, Hepatic lipase, Factor IXa, Factor VIIIa, Factor VIIa/TFPI, MMP-13, MMP-9, Spingolipid activator protein, PAI-1, Antithrombin III, Tissue factor pathway inhibitor (TFPI), Heparin cofactor II, APP, Thrombospondin-1, Thrombospondin-2, Pseudomonas exotoxin A, Lactoferrin, Rhinovirus and RAP.
A method of inducing an immune response against an antigenic molecule in a subject comprising administering to the subject an immunogenic amount of a purified complex comprising said antigenic molecule noncovalently bound to a CD91 ligand, wherein the CD91 ligand is selected from the group consisting of
- ApoE, Lipoprotein lipase, Hepatic lipase, Factor IXa, Factor VIIIa, Factor VIIa/TFPI, MMP-13, MMP-9, Spingolipid activator protein, PAI-1, Antithrombin III, Tissue factor pathway inhibitor (TFPI), Heparin cofactor II, APP, Thrombospondin-1, Thrombospondin-2, Pseudomonas exotoxin A, Lactoferrin, Rhinovirus and RAP, such that an immune response is induced.
A method of treating a disease or disorder amenable to treatment by induction of an immune response against an antigenic molecule, comprising administering to a subject having the disease or disorder an immunogenic amount of a purified complex comprising the antigenic molecule noncovalently bound to a CD91 ligand, wherein the CD91 ligand is selected from the group consisting of
- ApoE, Lipoprotein lipase, Hepatic lipase, Factor IXa, Factor VIIIa, Factor VIIa/TFPI, MMP-13, MMP-9, Spingolipid activator protein, PAI-1, Antithrombin III, Tissue factor pathway inhibitor (TFPI), Heparin cofactor II, APP, Thrombospondin-1, Thrombospondin-2, Pseudomonas exotoxin A, Lactoferrin, Rhinovirus and RAP.
Dependencies are inferred from the claim text.